Vijaya Diagnostic Centre Ltd.
Snapshot View

391.70 -1.10 ▼-0.3%

24 May 2022, 04:01:00 PM
Volume: 8,943

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.vijayadiagnostic.com
Market Cap 3,951.18 Cr.
Enterprise Value(EV) 3,804.42 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 8.33 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 47.04 Trailing Twelve Months Ending 2021-03
Industry PE 40.42 Trailing Twelve Months Ending 2021-03
Book Value / Share 43.72 Trailing Twelve Months Ending 2021-03
Price to Book Value 8.96 Calculated using Price: 391.70
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 10.20 Cr. 101,965,926 Shares
FaceValue 1
Company Profile

The company is the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing diagnostic chain by revenue for fiscal year 2020. It offer a one-stop solution for pathology and radiology testing services to its customers through its extensive operational network, which consists of 81 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata as on June 30, 2021.

The company offers a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. Its test menu includes pathology tests ranging from basic biochemistry and clinical pathology to cytogenetics and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including computerised tomography (CT) scans, magnetic resonance imaging (MRI) scans, single photon emission computed tomography (SPECT) and advanced positron emission tomography CT (PET CT).

It also offer a broad spectrum of health and wellness packages to its customers as per their requirements. The company focus on a customer centric approach to enhance the overall quality of its services for optimal customer satisfaction. For convenience of its customers, it provide value-added services such as home collection of specimens, house calls and various delivery or access modes (i.e., at diagnostic centres, SMS, email and web portal) for test reports. Several factors, including the strength of its brand, integrated services model, quality of its diagnostic services, center infrastructure and customer experience, convenience of its operational network and home collection in its core geographies are important differentiating factors in customers choosing it as their preferred diagnostic service provider, which helps it in retaining its customers, and sets it apart from its competitors.

Business area of the company

The company is one of the fastest-growing diagnostic chains in Southern India. It offers a one-stop solution for pathology and radiology testing services.

Awards, accreditations and recognitions

  • 2012: The company was recognised as one of the Best Imaging Centres in Hyderabad the Week- Hansa Research national survey 2012.
  • 2018: The company was awarded the Healthcare Leadership Award at the Telangana Healthcare Leadership Award 2018.
  • 2018: The Company was awarded the Fastest Growing Brand (Pride of the Nation) 2018-2019 by United Research Services.
  • 2018: The company’s centre at Gurgaon received the ISO 15189:2012 “Medical Laboratories - Requirements for quality and competence” for its facilities in the field of medical testing by NABL.
  • 2019: The company was awarded the Best Diagnostic Centre of the Year, India - 2019 by the Times Healthcare Achievers, The Times of India.
  • 2019: The company was awarded the Best Diagnostic Service Provider of the Year - 2019 at the Six Sigma Healthcare Excellence Awards, 2019.
  • 2019: The company’s centre at Hanamkonda received the ISO 15189:2012 “Medical Laboratories - Requirements for quality and competence” for its facilities in the field of medical testing by NABL.
  • 2019: The company’s centre at Kukatpally received scope of accreditation from NABH.
  • 2020: The Company was awarded the Most Trusted and Best Quality Diagnostic Services in India 2020 at the COVID Warriors Awards, 2020 by Topgallant Media.
  • 2020: The company’s centre at Himayatnagar received the ISO 15189:2012 “Medical Laboratories - Requirements for quality and competence” for its facilities in the field of medical testing by NABL.
  • 2020: The company’s centre at Sarojini Devi Road received scope of accreditation from NABH.
  • 2020: The company’s centre at Habsiguda received the ISO 15189:2012 by NABL.
  • 2021: The company has received the ‘Award of Excellence’ as the leading Imaging Centre (Multiple City) at the Radiology and Imaging Excellence Awards, 2021.
  • 2021: The company was awarded the Award of Excellence for leading from the front during the pandemic under the Leading Diagnostic Chain of the Year by Elets Technomedia.
  • 2021: The company received the certificate of recognition from the Economic Times as one of the Best Healthcare Brands -2021.

Major events and milestones

  • 2005: Business was transferred from proprietorship to the company.
  • 2008: First independent diagnostic centre in South India to get PET CT from Wipro GE Healthcare Private Limited.
  • 2014: Acquisition of majority shareholding in 'Medinova Diagnostic Services Limited'.
  • 2016: Investment by Karakoram Limited and Kedaara Capital Alternative Investment Fund - Kedaara Capital AIF 1.
  • 2021: First independent diagnostic centre in the State of Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare Private Limited.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.28%
1 Week
-16.97%
1 Month
-10.46%
3 Month
+3.79%
6 Month
-30.97%
1 Year
2 Year
5 Year
10 Year
3 years 2019-03 2020-03 2021-03
Return on Equity (%) 22.58 26.07 26.80
Return on Capital Employed (%) 31.56 35.47 37.97
Return on Assets (%) 11.42 14.11 16.72

Balance Sheet View Details

Particulars 4 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 207 275 359 420
Non Curr. Liab. 141 148 132 154
Curr. Liab. 57 59 44 65
Minority Int. 0 0 0 1
Equity & Liab. 405 481 535 640
Non Curr. Assets 268 294 296 388
Curr. Assets 137 186 239 252
Misc. Exp. not W/O
Total Assets 405 481 535 640

Profit Loss View Details

Particulars 3 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 293 339 377
Other Income 10 15 12
Total Income 303 354 389
Total Expenditure -184 -206 -211
PBIDT 118 148 178
Interest -14 -15 -15
Depreciation -40 -49 -50
Taxation -19 -21 -27
Exceptional Items
PAT 46 63 85
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 46 63 85
Adjusted EPS 102 138 19

Cash Flow View Details

Particulars 3 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 91 106 130
Cash Fr. Inv. -90 -31 -130
Cash Fr. Finan. -7 -30 -49
Net Change -7 46 -49
Cash & Cash Eqvt 10 56 7

Shareholding Pattern View Details

3 Qtrs 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 54.78 54.78 54.78
Public 45.22 45.22 45.22
Depository Receipts 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00

Announcements View Details

Fri, 20 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
we hereby submit the Annual Secretarial Compliance Report of the Company issued by Mr. Balaramakrishna Desina Practicing Company Secretary for the year ended March 31 2022.
Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Company is hosting Earnings Conference call for analysts and investors on Friday May 27 2022 at 2.00 PM IST to discuss on audited financial results of the Company for the quarter and year ended March 31 2022. The dial-in details of the call are enclosed.Please take the information on record.
Tue, 17 May 2022
Board Meeting Intimation for Approval Of Audited Financial Results For The FY Ended March 31 2022 And Dividend.
Vijaya Diagnostic Centre Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 inter alia to consider and approve Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 if any we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 26 2022 inter-alia to consider and approve the following;1. Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31 2022 and 2. Recommend the final dividend if any for the financial year ended on March 31 2022.Kindly take the information on record.

Technical Scans View Details

Tue, 24 May 2022
Close Crossing Last Week Low Close Crossing Last Week Low
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 6 Months High Decrease 6 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,371.20 914.30 -0.8%
Divi's Laboratories Ltd. 97,215.92 3,662.05 -6.0%
Cipla Ltd. 78,341.65 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. 72,413.55 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. 52,337.62 3,640.00 -2.2%
Gland Pharma Ltd. 47,375.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. 44,015.42 2,601.25 -0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.04 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 32.84 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 31.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.18 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.18 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 39.10 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.11 2,601.25 -0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 3.76 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.77 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.46 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 6.62 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.81 2,601.25 -0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 0.10 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,601.25 -0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,601.25 -0.6%